Lake Street initiated coverage on OptiNose with a new price target
$OPTN
Biotechnology: Pharmaceutical Preparations
Health Care
Lake Street initiated coverage of OptiNose with a rating of Buy and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2024 | $5.00 | Buy | H.C. Wainwright |
| 8/21/2023 | $3.00 | Buy | Lake Street |
| 10/21/2022 | $5.00 | Buy | Jefferies |
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,
SCHEDULE 13G - OptiNose, Inc. (0001494650) (Subject)
10-Q - OptiNose, Inc. (0001494650) (Filer)
8-K - OptiNose, Inc. (0001494650) (Filer)
4 - OptiNose, Inc. (0001494650) (Issuer)
3 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00
Lake Street initiated coverage of OptiNose with a rating of Buy and set a new price target of $3.00
Jefferies resumed coverage of OptiNose with a rating of Buy and set a new price target of $5.00
Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the fourth quarter on Thursday. Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share. The company said it expects first-quarter revenue to be between $119.5 million and $120.5 million versus estimates of $119.23 million. Doximity shares jumped 13.7% to $27.00 in the pre-market trading session. Here are some other stocks moving in pre-
Gainers Scorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 19.22% to $0.17. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out 2 days ago. Doximity (NYSE:DOCS) stock rose 11.4% to $26.45. The market value of their outstanding shares is at $4.9 billion. As per the news, the Q4 earnings report came out today. MEI Pharma (NASDAQ:MEIP) stock increased by 10.92% to $3.25. The company's market cap stands at $21.6 million. Akso Health Group (NASDAQ:AHG) stock increased by 9.36% to $0.69. The compan
SC 13G - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website
YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted to the new employees on their respective hire dates (October 7, 2024, and October 14, 2024) with an exe
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company decreases full year 2024 XHANCE net revenue guidance to be between $75.0 to $79.0 million and increases expected average net revenue per prescription guidance to be approximately $270 Company decreases full year 2024 operating expenses guidance to be between $90.0 to $93.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2024 and corporate updates, before market open, on Thursday, August 8, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 8, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at